1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Outsourced Small-molecule API Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Outsourced Small-molecule API Manufacturing Market, by Service Type
8.1.1. API Manufacturing
8.1.1.1. Market Revenue and Forecast
8.1.2. Process Development & Optimization
8.1.2.1. Market Revenue and Forecast
8.1.3. Analytical & QC Services
8.1.3.1. Market Revenue and Forecast
8.1.4. Regulatory Support Services
8.1.4.1. Market Revenue and Forecast
8.1.5. Packaging & Distribution Services
8.1.5.1. Market Revenue and Forecast
9.1. Outsourced Small-molecule API Manufacturing Market, by Synthesis Type
9.1.1. Synthetic/Chemical APIs
9.1.1.1. Market Revenue and Forecast
9.1.2. Biocatalysis/Enzyme-mediated Synthesis APIs
9.1.2.1. Market Revenue and Forecast
9.1.3. Fermentation-based Small Molecules
9.1.3.1. Market Revenue and Forecast
10.1. Outsourced Small-molecule API Manufacturing Market, by Therapeutic Area
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Cardiology
10.1.2.1. Market Revenue and Forecast
10.1.3. Central Nervous System (CNS) Disorders
10.1.3.1. Market Revenue and Forecast
10.1.4. Infectious Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Endocrine & Metabolic Disorders
10.1.5.1. Market Revenue and Forecast
10.1.6. Respiratory Diseases
10.1.6.1. Market Revenue and Forecast
10.1.7. Gastrointestinal Disorders
10.1.7.1. Market Revenue and Forecast
10.1.8. Pain Management
10.1.8.1. Market Revenue and Forecast
10.1.9. Autoimmune & Inflammatory Diseases
10.1.9.1. Market Revenue and Forecast
10.1.10. Others
10.1.10.1. Market Revenue and Forecast
11.1. Outsourced Small-molecule API Manufacturing Market, by End User
11.1.1. Pharmaceutical Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Biotechnology Companies
11.1.2.1. Market Revenue and Forecast
11.1.3. Generics Manufacturers
11.1.3.1. Market Revenue and Forecast
11.1.4. Virtual/Emerging Pharma Companies
11.1.4.1. Market Revenue and Forecast
11.1.5. Research Organizations
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service Type
12.1.2. Market Revenue and Forecast, by Synthesis Type
12.1.3. Market Revenue and Forecast, by Therapeutic Area
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service Type
12.1.5.2. Market Revenue and Forecast, by Synthesis Type
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service Type
12.1.6.2. Market Revenue and Forecast, by Synthesis Type
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service Type
12.2.2. Market Revenue and Forecast, by Synthesis Type
12.2.3. Market Revenue and Forecast, by Therapeutic Area
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service Type
12.2.5.2. Market Revenue and Forecast, by Synthesis Type
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service Type
12.2.6.2. Market Revenue and Forecast, by Synthesis Type
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service Type
12.2.7.2. Market Revenue and Forecast, by Synthesis Type
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service Type
12.2.8.2. Market Revenue and Forecast, by Synthesis Type
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service Type
12.3.2. Market Revenue and Forecast, by Synthesis Type
12.3.3. Market Revenue and Forecast, by Therapeutic Area
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service Type
12.3.5.2. Market Revenue and Forecast, by Synthesis Type
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service Type
12.3.6.2. Market Revenue and Forecast, by Synthesis Type
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service Type
12.3.7.2. Market Revenue and Forecast, by Synthesis Type
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service Type
12.3.8.2. Market Revenue and Forecast, by Synthesis Type
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service Type
12.4.2. Market Revenue and Forecast, by Synthesis Type
12.4.3. Market Revenue and Forecast, by Therapeutic Area
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service Type
12.4.5.2. Market Revenue and Forecast, by Synthesis Type
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service Type
12.4.6.2. Market Revenue and Forecast, by Synthesis Type
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service Type
12.4.7.2. Market Revenue and Forecast, by Synthesis Type
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service Type
12.4.8.2. Market Revenue and Forecast, by Synthesis Type
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service Type
12.5.2. Market Revenue and Forecast, by Synthesis Type
12.5.3. Market Revenue and Forecast, by Therapeutic Area
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service Type
12.5.5.2. Market Revenue and Forecast, by Synthesis Type
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service Type
12.5.6.2. Market Revenue and Forecast, by Synthesis Type
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area
12.5.6.4. Market Revenue and Forecast, by End User
13.1. Lonza
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Catalent, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Siegfried AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Piramal Pharma Solutions
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Pfizer Inc
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. 6S Pharma
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck KGaA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Cambrex
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson Matthey
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
